Eribulin
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angiosarcoma
Conditions
Angiosarcoma, Epithelioid Hemangioendothelioma
Trial Timeline
Jan 18, 2018 → Feb 1, 2026
NCT ID
NCT03331250About Eribulin
Eribulin is a phase 2 stage product being developed by Eisai for Angiosarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT03331250. Target conditions include Angiosarcoma, Epithelioid Hemangioendothelioma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03840772 | Phase 2 | Completed |
| NCT03637868 | Phase 2 | Withdrawn |
| NCT03331250 | Phase 2 | Active |
| NCT03027245 | Pre-clinical | Completed |
| NCT01669252 | Phase 2 | Completed |
| NCT00908908 | Phase 1 | Completed |
Competing Products
6 competing products in Angiosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avelumab + Paclitaxel | Merck | Phase 2 | 52 |
| Pembrolizumab plus Lenvatinib | Merck | Phase 2 | 52 |
| Pazopanib + Paclitaxel | Novartis | Phase 2 | 52 |
| regorafenib | Bayer | Phase 2 | 49 |
| Vusolimogene Oderparepvec (VO) + Pembrolizumab | Replimune | Phase 2 | 44 |
| AGEN2034 + AGEN1884 | Agenus | Phase 2 | 44 |